Valproate is used for treatment of epilepsy and bipolar disorders. It is the most effective treatment for generalised or unclassified epilepsy [1]. However, exposure to valproate in utero is also associated with substantial teratogenic risks, including major congenital malformations (around 10%) [2], cognitive (30-40% exposed have significant reduction of IQ [3] and neurodevelopmental disorders such as autism spectrum disorder [4]. This has led to the introduction of measures to reduce the use of valproate in women of childbearing potential.
3
ABR
ABR
0